Levetiracetam Tablet, Film Coated
Product Images NDC 55154-4171

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-4171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (0348fec4 D919 4307 Ac90 35360819bc00 00)

Bag Label (0348fec4 D919 4307 Ac90 35360819bc00 00)
Levetiracetam Tablets USP 500 mg film-coated tablets packaging label showing a 10-tablet unit dose. The label indicates dosage instructions are in the product insert and includes storage conditions, pharmacist dispensing instructions, and distribution details from Aurobindo Pharma USA, Major Pharmaceuticals, and Cardinal Health.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The graph shows responder rates of 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day, with statistical significance indicated for both Levetiracetam groups versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' comparing the percentage of patients achieving this reduction among three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The graph notes statistical significance for both Levetiracetam groups versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' showing percentage of patients responding to treatment. The chart compares placebo (14.4% responder rate, N=104) with Levetiracetam 3000 mg/day (39.4% responder rate, N=180). A statistical significance marker is noted for Levetiracetam versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
Bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' compares percentage of patients responding to placebo versus Levetiracetam. Placebo group shows 19.6%, Levetiracetam group shows 44.6%, with a noted statistical significance versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar graph showing the responder rate for patients aged 1 month to under 4 years in a study, comparing placebo and Levetiracetam. The y-axis represents the percentage of patients achieving at least 50% reduction from baseline. The placebo group shows a responder rate of 19.6%, and the Levetiracetam group shows 43.1%, with a statistically significant difference indicated.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart showing responder rate (% of patients with ≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7. The chart compares placebo (45.2%, N=84) and Levetiracetam (72.2%, N=79), indicating a statistically significant higher responder rate for Levetiracetam versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam illustrating its molecular framework, including a pyrrolidone ring and associated functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.